ERA-EDTA 2021 – Novartis’s iptacopan sets the bar in rare kidney disease
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
Asco 2021 justifies Novartis’s radioligand Vision
177Lu-PSMA-617 shows impressive survival results in the Vision study, but early use will be key to fulfilling its potential.
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
US appetite for Covid-19 treatments remains undiminished
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Roche remains big pharma’s biggest R&D spender
As Covid-19 spending pushes the sector’s R&D bill ever higher, Lilly continues to plough the most back in as Sanofi applies the brakes.
Lilly leads the big pharma pack on pipeline value
Huge hopes for diabetes and Alzheimer’s projects swell Lilly’s pipeline valuation, with Glaxosmithkline and Abbvie looking bare in comparison.
Asco 2021 – Abstract lift drives first stock moves
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
